Erhardt DP, et al. – Given that combination therapies for patients with rheumatoid arthritis with inadequate response to single-agent methotrexate (MTX) include the addition of tumor necrosis factor inhibitors (TNFi) or the addition of sulfasalazine (SSZ) and hydroxychloroquine to MTX (triple therapy [TT]), experts compared the persistence and adherence rates between these two combination therapies in US Veterans with RA, and reported the reasons for discontinuation of combination treatment patients with RA. Findings suggested that differences in persistence and adherence between the MTX-TNFi and TT groups appear to be primarily related to adverse drug events that were most often attributed to SSZ. For the MTX-TNFi group, adherence was higher (26%) than the TT group (11%).